Vyv is a technology company.
Vyv has raised $4.5M across 2 funding rounds.
Vyv has raised $4.5M in total across 2 funding rounds.
# High-Level Overview
Vyv is a health-technology company that designs and manufactures UV-free antimicrobial LED lighting systems that continuously kill bacteria, viruses, fungi, mold, and other microorganisms using 405nm visible light technology.[1][2] Founded in 2013, Vyv serves diverse markets including healthcare facilities, food and beverage manufacturing, pharmaceutical production, hospitality, schools, automotive, and residential applications.[3] The company solves a critical problem: how to maintain continuous microbial control in indoor environments without relying on harsh chemicals, UV radiation, or manual cleaning protocols. With multiple U.S. patents and proven efficacy against pathogens including MRSA, E. coli, Salmonella, and non-enveloped viruses, Vyv has demonstrated strong growth momentum, recently securing major partnerships and publishing research in *Nature* on its antimicrobial technology's impact on global food safety and healthcare.[1]
The company is female-founded and led, positioning it distinctly within the health-tech sector.[4] Rather than selling a one-time product, Vyv offers a continuous cleaning solution that integrates into existing lighting infrastructure—from overhead surgical suite lights to embedded applications in consumer products and industrial processes.[3]
# Origin Story
Vyv emerged in 2013 as a response to the need for safer, more sustainable antimicrobial solutions.[1][3] The founding team comprised engineers, scientists, designers, and health experts united by a mission to solve real-world contamination problems without exposing people to harmful UV radiation or toxic chemicals.[2] The company's breakthrough came with the development of the world's first single white light antimicrobial diode, a patented innovation that unlocked new applications across industries.[4] This foundational technology has since evolved into a portfolio of products and platforms, with the company holding 21 granted patents and 29 pending as of recent reports.[4]
# Core Differentiators
# Role in the Broader Tech Landscape
Vyv operates at the intersection of three powerful trends: the post-pandemic heightened focus on hygiene and infection control, the shift toward sustainable and chemical-free solutions, and the maturation of LED technology as a platform for novel applications. The company's timing is particularly advantageous as industries face mounting pressure to reduce chemical use in food processing and healthcare while maintaining rigorous safety standards.
Vyv's influence extends beyond its direct market applications. By demonstrating that visible light can be weaponized against pathogens, the company has validated an entirely new category of antimicrobial technology, potentially inspiring adjacent innovations in materials science and environmental control. Its partnerships with major players and publication in *Nature* signal that the technology has crossed from niche health-tech into mainstream scientific and commercial recognition.[1]
The company also exemplifies how female-founded ventures in deep tech can achieve significant scale and impact, potentially influencing venture capital allocation patterns toward underrepresented founders in the health-tech space.
# Quick Take & Future Outlook
Vyv stands at an inflection point. With recent major partnerships, peer-reviewed validation, and expansion across nine regions, the company appears positioned for accelerated growth in markets where continuous antimicrobial control delivers measurable ROI—particularly healthcare, food safety, and hospitality.[1] The next frontier likely involves deeper penetration into residential and consumer product categories, where the safety profile of 405nm light becomes a compelling selling point for health-conscious consumers.
The broader question is whether Vyv can establish 405nm antimicrobial lighting as the default standard for new construction and retrofits, similar to how LED lighting displaced incandescent bulbs. Success hinges on scaling manufacturing, reducing costs, and building awareness among architects, facility managers, and consumers. As regulatory bodies increasingly scrutinize chemical disinfectants and UV exposure risks, Vyv's technology may transition from innovative differentiator to industry baseline—a shift that would validate the company's founding premise while reshaping how we think about environmental hygiene.
Vyv has raised $4.5M in total across 2 funding rounds.
Vyv's investors include CITG Capital, Connectivity Capital Partners, Great Oaks Venture Capital, GSV Acceleration, Long Journey Ventures, MATH Venture Partners, Next Play Ventures, Plum Alley Investments, S2G Ventures, Spring Capital, Jason Henrichs, Jay Baer.
Vyv has raised $4.5M across 2 funding rounds. Most recently, it raised $4.0M Seed in January 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2018 | $4.0M Seed | CITG Capital, Connectivity Capital Partners, Great Oaks Venture Capital, GSV Acceleration, Long Journey Ventures, MATH Venture Partners, Next Play Ventures, Plum Alley Investments, S2G Ventures, Spring Capital, Jason Henrichs, Jay Baer, Joe Fernandez, Ligaya Tichy, Scott Banister, Trevor Folsom | |
| Jul 1, 2013 | $450K Seed | SOSV |